Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker IKT
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 10, 2026 | IKT Inhibikase Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 20, 2026 | IKT Inhibikase Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 20, 2026 | IKT Inhibikase Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Sep 8, 2026 | IKT Inhibikase Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 26, 2026 | IKT Inhibikase Therapeutics, Inc. | 4.01 Changes in Registrant's Certifying Accountant | 8-K | 8-K ↗ |
| Aug 11, 2026 | IKT Inhibikase Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 29, 2026 | IKT Inhibikase Therapeutics, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Jul 23, 2026 | IKT Inhibikase Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 14, 2026 | IKT Inhibikase Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 29, 2026 | IKT Inhibikase Therapeutics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 29, 2026 | IKT Inhibikase Therapeutics, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Jun 29, 2026 | IKT Inhibikase Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 12, 2026 | IKT Inhibikase Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 7, 2026 | IKT Inhibikase Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Mar 26, 2026 | IKT Inhibikase Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Dec 19, 2025 | IKT Inhibikase Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 21, 2025 | IKT Inhibikase Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 21, 2025 | IKT Inhibikase Therapeutics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 20, 2025 | IKT Inhibikase Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 14, 2025 | IKT Inhibikase Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 14, 2025 | IKT Inhibikase Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 14, 2025 | IKT Inhibikase Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 30, 2025 | IKT Inhibikase Therapeutics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 14, 2025 | IKT Inhibikase Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 14, 2025 | IKT Inhibikase Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Apr 14, 2025 | IKT Inhibikase Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Mar 27, 2025 | IKT Inhibikase Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 24, 2025 | IKT Inhibikase Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 24, 2025 | IKT Inhibikase Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Feb 24, 2025 | IKT Inhibikase Therapeutics, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Feb 24, 2025 | IKT Inhibikase Therapeutics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Feb 18, 2025 | IKT Inhibikase Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 18, 2025 | IKT Inhibikase Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jan 29, 2025 | IKT Inhibikase Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jan 6, 2025 | IKT Inhibikase Therapeutics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jan 6, 2025 | IKT Inhibikase Therapeutics, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Dec 5, 2024 | IKT Inhibikase Therapeutics, Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
37 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances